葛均波高福朱同玉展望 十四五 ，提升中国创新话语权|高福_新浪科技_新浪网 sina.com.cn - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from sina.com.cn Daily Mail and Mail on Sunday newspapers.
The Latest: SKorean economy shrinks for 1st time in 22 years
The Associated Press
FacebookTwitterEmail 21
1of21A man wearing a face mask as a precaution against the coronavirus, walks past in front of an advertisement of an opera performance outside of a theater in Seoul, South Korea, Wednesday, March 3, 2021.Lee Jin-man/APShow MoreShow Less
2of21Armelio Acosta receives the Johnson & Johnson COVID-19 vaccine at a FEMA mass vaccination center at Miami Dade College, Wednesday, March 3, 2021, in North Miami, Fla. This is one of four FEMA sites in Florida that opened Wednesday with capacity to vaccinate up to 3,000 people a day seven days a week.Marta Lavandier/APShow MoreShow Less
(1)
PRESS RELEASE
Nyxoah announces the publication of first positive clinical data in an OSA patient suffering from Complete Concentric Collapse (CCC)
Mont-Saint-Guibert, Belgium - 3
rd March 2021 - Nyxoah SA (Euronext: NYXH) ( Nyxoah or the Company ), a health-technology company focused on the development and commercialization of innovative solutions and services to treat Obstructive Sleep Apnea (OSA), today announces the publication of an article presenting the first case of successful treatment of an OSA patient suffering from Complete Concentric Collapse (CCC) with Nyxoah s unique Genio bilateral neurostimulation solution
1.
Patients suffering from Complete Concentric Collapse (CCC) currently amount for at least 30% of the existing OSA patient population. For now, these patients are contra-indicated for existing Hypoglossal Nerve Stimulation OSA therapies. Nyxoah is currently conducting the BETTER SLEEP study, that aims to assess the effectiveness of the Genio system bila
New poll spotlights a major gap in testing for hearing loss in older adults
Eighty percent of Americans over 50 say their primary care doctor hasn t asked about their hearing in the past two years, and nearly as many - 77% haven t had their hearing checked by a professional in that same time, according to a new national poll report.
That s despite a growing body of evidence about the importance of hearing to other aspects of life, from dementia and risk of falls to the ability to stay connected to friends and family.
Men were more likely than women to say they d had a recent hearing screening or test, and so were people ages 65 to 80 compared with those in their pre-Medicare years, according to the findings from the National Poll on Healthy Aging, based at the University of Michigan s Institute for Healthcare Policy and Innovation. But even among men and those over 65, 72% hadn t been tested.
(0)
Forendo Pharma, a clinical-stage drug development company focusing on novel treatments in women s health, today announced the completion of Phase 1 studies in healthy volunteers for its lead development program in endometriosis, FOR-6219, and provided a development outlook. The successfully concluded Phase 1 program demonstrated that FOR-6219, a HSD17B1 enzyme-targeting small-molecule, was safe and well-tolerated and delivered additional results supporting Forendo s therapeutic concept. The company is now planning the Phase 2 program including endometriosis patients in the US. The now completed Phase 1 program delivered an initial body of tolerability, safety and pharmacokinetic data. For chronic endometriosis treatment, tolerability and a lack of systemic estrogen deficiency-related side effects are of the utmost importance as we see current therapies struggling to be widely adopted due to their side effect profiles. A local effect on the target tissue with our intracrinolog